Among various antidiabetic agents, sodium-glucose cotransporter-2 inhibitors (SGLT2is) have emerged as a novel therapeutic class in the treatment of T2DM due to their unique mechanism of action and clinical benefits [4–9]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.